Daily News Podcast

Rivaroxaban data abound at ESC 2018


 

New results from the ASCEND trial show that neither aspirin nor fish oil provides any net clinical benefit for primary cardiovascular prevention in patients with diabetes. Also today, rivaroxaban is no help for heart failure outcomes, VTE risk is unchanged by rivaroxaban taken after discharge, and the AAP cautions against marijuana use during pregnancy and breastfeeding. Subscribe to the MDedge Daily News wherever you get your podcasts.

Amazon Alexa
Apple Podcasts
Spotify

Recommended Reading

Psoriasis registry study provides more data on infliximab’s infection risk
MDedge Internal Medicine
New guidelines remap adult congenital heart disease
MDedge Internal Medicine
FDA approves first EpiPen generic
MDedge Internal Medicine
Cardiovascular risk management supported for type 2 diabetes
MDedge Internal Medicine
An epidemic of non-alcoholic fatty liver disease
MDedge Internal Medicine
Sleepio app tied to reducing insomnia, depression
MDedge Internal Medicine
5 digital HIPAA myths
MDedge Internal Medicine
Screen for cervical cancer based on age, risk
MDedge Internal Medicine
Is it time for PCPs to take over chronic HCV?
MDedge Internal Medicine
Lorcaserin shows cardiovascular safety
MDedge Internal Medicine